Moreover, female patients with advanced lung cancer achieved a significantly greater benefit from the combined therapy of chemotherapy and anti-PD-1/PD-L1, whereas male patients responded better to anti-PD-1 alone15. This evidence concerns the gene PDCD1 and lung carcinoma.